Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
- 1 December 1997
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 154 (12) , 1760-1762
- https://doi.org/10.1176/ajp.154.12.1760
Abstract
OBJECTIVE: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. METHOD: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. RESULTS: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. CONCLUSIONS: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually. (Am J Psychiatry 1997; 154:1760–1762)Keywords
This publication has 7 references indexed in Scilit:
- Venlafaxine withdrawal reactionsAmerican Journal of Psychiatry, 1996
- Serotonin Reuptake Inhibitor WithdrawalJournal of Clinical Psychopharmacology, 1996
- Possible venlafaxine withdrawal syndromeAmerican Journal of Psychiatry, 1996
- Antidepressant Withdrawal SyndromeCNS Drugs, 1996
- Discontinuation reactions following sertralineBiological Psychiatry, 1995
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960